Molecular fingerprints of cardiovascular toxicities of immune checkpoint inhibitors
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Molecular fingerprints of cardiovascular toxicities of immune checkpoint inhibitors ; day:17 ; month:7 ; year:2024 ; pages:1-19
Basic research in cardiology ; (17.7.2024), 1-19
- Creator
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s00395-024-01068-8
- URN
-
urn:nbn:de:101:1-2410080806009.568484397578
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:38 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Gergely, Tamás G.
- Drobni, Zsófia D.
- Sayour, Nabil V.
- Ferdinandy, Péter
- Varga, Zoltán V.
- SpringerLink (Online service)
Other Objects (12)
Risk Factors for Immune Checkpoint Inhibitor–Mediated Cardiovascular Toxicities
Imaging Features of Toxicities by Immune Checkpoint Inhibitors in Cancer Therapy
Cardiovascular Toxicity of Immune Checkpoint Inhibitors: A Guide for Clinicians
Methylated Organic Metabolites of Arsenic and their Cardiovascular Toxicities
A retrospective analysis of cardiovascular adverse events associated with immune checkpoint inhibitors
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
Case report: a successful treatment with immune checkpoint inhibitors was associated with severe dermatologic toxicities in a patient with double primary malignancies
Neurosarcoidosis following Immune Checkpoint Inhibition
Immune Checkpoint Inhibitor Rechallenge After Prior Immune Toxicity
Immune checkpoint analysis in lip cancer
Cancer immunotherapy beyond immune checkpoint inhibitors
Immune checkpoint inhibitor-related acral vasculitis
Risk Factors for Immune Checkpoint Inhibitor–Mediated Cardiovascular Toxicities
Imaging Features of Toxicities by Immune Checkpoint Inhibitors in Cancer Therapy
Cardiovascular Toxicity of Immune Checkpoint Inhibitors: A Guide for Clinicians
Methylated Organic Metabolites of Arsenic and their Cardiovascular Toxicities
A retrospective analysis of cardiovascular adverse events associated with immune checkpoint inhibitors
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
Case report: a successful treatment with immune checkpoint inhibitors was associated with severe dermatologic toxicities in a patient with double primary malignancies
Neurosarcoidosis following Immune Checkpoint Inhibition
Immune Checkpoint Inhibitor Rechallenge After Prior Immune Toxicity
Immune checkpoint analysis in lip cancer
Cancer immunotherapy beyond immune checkpoint inhibitors
Immune checkpoint inhibitor-related acral vasculitis
Risk Factors for Immune Checkpoint Inhibitor–Mediated Cardiovascular Toxicities
Imaging Features of Toxicities by Immune Checkpoint Inhibitors in Cancer Therapy
Cardiovascular Toxicity of Immune Checkpoint Inhibitors: A Guide for Clinicians
Methylated Organic Metabolites of Arsenic and their Cardiovascular Toxicities
A retrospective analysis of cardiovascular adverse events associated with immune checkpoint inhibitors
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
Case report: a successful treatment with immune checkpoint inhibitors was associated with severe dermatologic toxicities in a patient with double primary malignancies
Neurosarcoidosis following Immune Checkpoint Inhibition
Immune Checkpoint Inhibitor Rechallenge After Prior Immune Toxicity
Immune checkpoint analysis in lip cancer
Cancer immunotherapy beyond immune checkpoint inhibitors